3
Clinical Trials associated with BRL-303 / Not yet recruitingEarly Phase 1IIT An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system. This study aims to evaluate the safety and efficacy of the treatment with universal BCMA and CD19 CART.
/ Not yet recruitingEarly Phase 1 A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 for the Treatment of Refractory Lupus Nephritis
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
/ Not yet recruitingPhase 1 靶向CD19基因修饰的异体嵌合抗原受体T细胞注射液(BRL-303)治疗中度或重度难治性系统性红斑狼疮安全性和有效性的I期临床研究
[Translation] A Phase I clinical study on the safety and efficacy of CD19 gene-modified allogeneic chimeric antigen receptor T-cell injection (BRL-303) in the treatment of moderate to severe refractory systemic lupus erythematosus.
1. 评估BRL-303在中度或重度难治性系统性红斑狼疮(SLE)受试者中的安全性和耐受性
2. 确定BRL-303在中度或重度难治性SLE受试者中的Ⅱ期推荐剂量(RP2D)
[Translation] 1. Evaluate the safety and tolerability of BRL-303 in subjects with moderate or severe refractory systemic lupus erythematosus (SLE).
2. Determine the phase II recommended dose (RP2D) of BRL-303 in subjects with moderate or severe refractory SLE.
100 Clinical Results associated with BRL-303
100 Translational Medicine associated with BRL-303
100 Patents (Medical) associated with BRL-303
100 Deals associated with BRL-303